Bellini Chiara, Horváti Kata
Hevesy György PhD School of Chemistry, Eötvös Loránd University, 1117 Budapest, Hungary.
MTA-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University, 1117 Budapest, Hungary.
Cells. 2020 Dec 15;9(12):2673. doi: 10.3390/cells9122673.
The World Health Organization (WHO) herald of the "End TB Strategy" has defined goals and targets for tuberculosis prevention, care, and control to end the global tuberculosis endemic. The emergence of drug resistance and the relative dreadful consequences in treatment outcome has led to increased awareness on immunization against (). However, the proven limited efficacy of Bacillus Calmette-Guérin (BCG), the only licensed vaccine against , has highlighted the need for alternative vaccines. In this review, we seek to give an overview of infection and failure of BCG to control it. Afterward, we focus on the protein- and peptide-based subunit vaccine subtype, examining the advantages and drawbacks of using this design approach. Finally, we explore the features of subunit vaccine candidates currently in pre-clinical and clinical evaluation, including the antigen repertoire, the exploited adjuvanted delivery systems, as well as the spawned immune response.
世界卫生组织（WHO）发布的“终止结核病战略”为结核病的预防、护理和控制制定了目标，以终结全球结核病流行。耐药性的出现以及治疗结果相对可怕的后果，提高了人们对针对（）进行免疫接种的认识。然而，唯一获得许可的抗（）疫苗卡介苗（BCG）已证实疗效有限，这凸显了替代疫苗的必要性。在本综述中，我们旨在概述（）感染以及卡介苗控制感染失败的情况。之后，我们将重点关注基于蛋白质和肽的亚单位疫苗亚型，研究使用这种设计方法的优缺点。最后，我们探讨目前处于临床前和临床评估阶段的亚单位疫苗候选物的特点，包括抗原库、所采用的佐剂递送系统以及引发的免疫反应。
